Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow SELLAS Life Sciences Group, Inc.

Get SEC filing alerts via email and in your feed for SELLAS Life Sciences Group, Inc.

SLS

SELLAS Life Sciences Group, Inc.

About SELLAS Life Sciences Group, Inc.

Sellas Life Sciences Group is a biopharmaceutical company developing novel cancer immunotherapies and targeted treatments. Its core focus includes peptide-based vaccines and small molecule inhibitors targeting cancers such as AML, solid tumors, and lymphomas. The company’s products aim to activate the immune system against tumor-specific antigens, leveraging proprietary technology and strategic licensing to address unmet medical needs in oncology markets worldwide.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from SELLAS Life Sciences Group, Inc.

1
1
SELLAS Life Sciences Group, Inc. SELLAS Life Sciences Reports $8.4 Million Net Loss in Q1 2026, Increases Cash Reserves to $107.1 Million

Via official filing (AI summary) | 23 days ago | 0 comments

2
1
SELLAS Life Sciences Group, Inc. SELLAS Life Sciences Reports $26.9 Million Net Loss for 2025, Decreased Operating Expenses

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
SELLAS Life Sciences Group, Inc. SELLAS Life Sciences Reports Q3 2025 Financial Results with Improved Net Loss

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
SELLAS Life Sciences Group, Inc. SELLAS Life Sciences Reports Q2 2025 Financial Results with Reduced Net Loss

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
SELLAS Life Sciences Group, Inc. SELLAS Life Sciences Reports Improved Q1 2025 Financial Results with Reduced Net Loss

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
SELLAS Life Sciences Group, Inc. SELLAS Life Sciences Reports $30.9 Million Net Loss for 2024, Decreased Operating Expenses

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
SELLAS Life Sciences Group, Inc. Sellas Life Sciences Reports Improved Financial Position, Reduced Losses in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments